Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by MyoKardia

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mavacamten

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Available

            Deal Size: Not Available Upfront Cash: Not Available

            Deal Type: Not Available November 02, 2020

            Details:

            Two of the abstracts accepted for presentation focus on echocardiographic and cardiac magnetic resonance imaging (CMR) data from the pivotal EXPLORER-HCM clinical trial of mavacamten.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mavacamten

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bristol-Myers Squibb

            Deal Size: $13,100.0 million Upfront Cash: $13,100.0 million

            Deal Type: Acquisition October 05, 2020

            Details:

            The acquisition provides Bristol Myers Squibb access to Mavacamten, a potential first-in-class myosin inhibitor with compelling data in the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Danicamtiv

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-491

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 09, 2020

            Details:

            First patient has been dosed in the company’s Phase 2 clinical trial of danicamtiv (formerly MYK-491) in people with primary dilated cardiomyopathy (DCM) thought to be caused by genetic mutations of the sarcomere.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mavacamten

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: LianBio

            Deal Size: $187.0 million Upfront Cash: Undisclosed

            Deal Type: Partnership August 11, 2020

            Details:

            The partnership will initially pursue a registration strategy for mavacamten in China for obstructive HCM, with plans for additional indications to follow, in keeping with MyoKardia’s development strategy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mavacamten

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 10, 2020

            Details:

            Data from the pivotal Phase 3 clinical trial of patients with symptomatic, obstructive hypertrophic cardiomyopathy will form the foundation of the company’s NDA for mavacamten, which MyoKardia intends to submit in the first quarter of 2021.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mavacamten

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 03, 2020

            Details:

            VALOR-HCM will enroll individuals with obstructive hypertrophic cardiomyopathy (HCM) who have been referred for septal reduction therapy (SRT) and are refractory to current therapeutic options, including those who have severe symptoms (NYHA Class IV).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mavacamten

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 23, 2020

            Details:

            U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to mavacamten, a novel, oral, allosteric modulator of cardiac myosin, for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Recipient: Fulcrum Therapeutics

            Deal Size: $465.0 million Upfront Cash: $12.5 million

            Deal Type: Collaboration July 21, 2020

            Details:

            Under the agreement, MyoKardia will access Fulcrum’s unique, proprietary target discovery engine to identify therapeutics that control the expression of genes that are known to be underlying drivers of genetic cardiomyopathies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Danicamtiv

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-491

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 19, 2020

            Details:

            Danicamtiv is MyoKardia’s lead activator candidate designed to increase the contractility of the heart with minimal or no effect on myocardial relaxation and compliance (diastolic function) by acting directly on the proteins in the heart muscle responsible for contraction.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mavacamten

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: BofA Securities

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Public Offering May 12, 2020

            Details:

            The net proceeds support MyoKardia's planned regulatory approval process and commercial launch of mavacamten, if approved to fund ongoing and later-stage clinical studies of mavacamten in non-obstructive HCM, danicamtiv and MYK-224 in the area of Cardiovascular Diseases.

            PharmaCompass